Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Open Label, Single-Arm, Multi-Center, Multiple Dose, 14-Day Study to Evaluate the Safety, Efficacy, and Frequency of Intravesical Administration of VNX001 in Acute Treatment of Subjects With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) Who Have an Episode of Acute Bladder Pain of Moderate to Severe Intensity

NCT06394830 is registered in ClinicalTrials.gov with Vaneltix Pharma, Inc. as lead sponsor.

NCT NCT06394830
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06394830 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Open Label, Single-Arm, Multi-Center, Multiple Dose, 14-Day Study to Evaluate the Safety, Efficacy, and Frequency of Intravesical Administration of VNX001 in Acute Treatment of Subjects With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) Who Have an Episode of Acute Bladder Pain of Moderate to Severe Intensity
Lead sponsor
Vaneltix Pharma, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
December 13, 2024
Completion date
June 30, 2026
Enrollment
50 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

bladder pain syndrome, interstitial cystitis